TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04197843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviCam (ANKON)
Description: The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
Study: NCT01159054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Nicotinic Acid (Niaspan)
Description: Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
Study: NCT00575926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LingZhi capsule
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LingZhi capsule
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
Study: NCT01527734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: 15ug and 30ug once or twice a day for 1 or 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1ml once or twice a day for 1 or 2 days.
Study: NCT03156660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight gain prevention (Group 1)
Description: Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (Group 2)
Description: Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided intervention (Group 3)
Description: Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale
Study: NCT00500903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
Study: NCT02452723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC
Study: NCT03167099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Weight Bearing
Description: full weight bearing after fixation of a distal femur fracture
Study: NCT02468557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
Study: NCT03602014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Northera
Description: Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Northera
Description: Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
Study: NCT00843453

Intervention type: OTHER
Group type: OTHER
Intervention: blood collection
Description: blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment (cyanocobalamin nasal spray)
Description: cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
Study: NCT00631176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-In-Time Training
Description: On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
Study: NCT01533428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8%
Description: Capsaicin 8% transdermal delivery system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Patch
Study: NCT05979181

Intervention type: PROCEDURE
Intervention: Cesarean hysterectomy
Description: Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)

Intervention type: PROCEDURE
Intervention: Cesarean hysterectomy
Description: Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
Study: NCT03055533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headsprout reading program
Description: Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
Study: NCT00418483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 25 mg
Description: Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 50 mg
Description: Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 75 mg
Description: Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 100 mg
Description: Plasmin (Human) 100 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 125 mg
Description: Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 150 mg
Description: Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 175 mg
Description: Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study: NCT03994445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone-Based Intervention
Description: We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives .
Study: NCT04524871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT2152
Description: NKT2152 will be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO-108 1200 mg
Description: IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
Study: NCT04452149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download
Description: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download
Description: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication intervention
Description: Risk status guided medication intervention.
Study: NCT03136445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA).
Description: IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV (saline) or oral placebo tablets
Study: NCT03306212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent serial casting
Study: NCT01311674

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine
Description: Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
Study: NCT02917707

Intervention type: OTHER
Intervention: normal colorectal tissues
Description: The investigators will extract total protein, DNA and RNA from these groups.

Intervention type: OTHER
Intervention: normal colorectal tissues
Description: The investigators will extract total protein, DNA and RNA from these groups.

Intervention type: OTHER
Intervention: normal colorectal tissues
Description: The investigators will extract total protein, DNA and RNA from these groups.
Study: NCT03283904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Description: School-based multicomponent intervention
Study: NCT01188434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITSAN
Description: integrated behavioral intervention for substance abuse, parenting skills, and basic needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Services as usual referred by child welfare
Study: NCT03580733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin antifungal therapy
Description: caspofungin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01657058

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend powder in hydrophobic matrix
Description: 5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend in pre hydrated form
Description: 0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble viscous fibre blend
Description: 0g soluble viscous fibre blend margarine + white bread + jello

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend premixed with ½ carbohydrate gel
Description: Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble viscous fibre blend, ½ carbohydrate jello
Description: Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
Study: NCT04642508

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prepectoral reconstruction
Description: Immediate prepectoral breast reconstruction in women requiring a mastectomy
Study: NCT03538470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: * Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool
Study: NCT03520764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New infant formula with synbiotics
Description: Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula with prebiotics
Description: Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
Study: NCT00344461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, FTC, and Tenofovir
Description: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
Study: NCT03930342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native-CHOICES
Description: Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
Study: NCT02069444

Intervention type: PROCEDURE
Intervention: Macintosh laryngoscope
Description: intubation criterias withMacintosh laryngoscopein pediatric patients

Intervention type: PROCEDURE
Intervention: Truview EVO2 laryngoscope
Description: intubation criterias with Truview EVO2 laryngoscope in pediatric patients
Study: NCT02660632

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Description: Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath catheter block
Description: Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
Study: NCT03691116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Profile
Description: Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Ordinary psychological assessment and counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Ordinary psychological assessment and counseling.
Study: NCT03294512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAWDS data entry on app
Description: Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
Study: NCT03031522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.
Study: NCT04830475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation (NIV)
Description: Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Venturi Mask
Description: Patients were offered VenturiMask with Fio2 60% at 15 l / m.
Study: NCT02815462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: - Usual hospital Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: * For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - For low risk patients, PNs will continue usual hospital care.
Study: NCT01417572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
Study: NCT02668224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrasens
Description: Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual activities
Description: The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
Study: NCT00251862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based decision aid plus personalized risk assessment
Description: Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
Study: NCT03087851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous infusion of 5 mg zoledronic acid
Study: NCT03031522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.
Study: NCT00251862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based decision aid alone
Description: Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic website
Description: Patients review a generic website that discuss ways to reduce overall cancer risk.
Study: NCT01587534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norzyme
Description: Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Study: NCT03087851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous infusion of 5 mg zoledronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous infusion of 5 mg zoledronic acid